US Patent 10,039,779: Claim Scope, Harvoni Formulation Protection, Expiration and Generic Risk

US Patent 10,039,779 protects the specific fixed-dose tablet formulation used for Harvoni, the ledipasvir/sofosbuvir combination. Its strongest claims require a defined solid dispersion of amorphous ledipasvir in copovidone, crystalline sofosbuvir with specified XRPD peaks, and a narrow excipient system. Claims 15 and 16 are the principal composition claims because they recite the commercial 90 mg/400 mg tablet at both percentage and absolute-weight levels.

The patent is materially narrower than a basic composition-of-matter patent covering ledipasvir or sofosbuvir. A competing product must practice every limitation of at least one asserted claim. The patent’s principal commercial value is formulation blocking power, not broad control over either active pharmaceutical ingredient.

What drug and formulation does US Patent 10,039,779 protect?

US Patent 10,039,779 protects a fixed-dose tablet containing:

Component	Claimed commercial amount
Ledipasvir/copovidone solid dispersion	180 mg
Ledipasvir active ingredient	90 mg
Sofosbuvir	400 mg
Lactose monohydrate	165 mg
Microcrystalline cellulose	180 mg
Croscarmellose sodium	50 mg
Colloidal silicon dioxide	10 mg
Magnesium stearate	15 mg
Total tablet core weight	1,000 mg

The formulation corresponds to the active-ingredient strengths of Harvoni, marketed by Gilead Sciences for chronic hepatitis C virus infection. The patent claims the drug product through a combination of composition, solid-state, excipient, dosage-form and treatment limitations (U.S. Patent No. 10,039,779, 2018; FDA, Harvoni labeling).

What is the protected solid dispersion?

The ledipasvir component must be dispersed in a polymer matrix formed by copovidone. The weight ratio of ledipasvir to copovidone must be approximately 1:1, and more than 70% of the ledipasvir must be amorphous.

In the commercial 180 mg dispersion:

Approximately 90 mg is ledipasvir.
Approximately 90 mg is copovidone.
More than 70% of the ledipasvir is in the amorphous state.

This limitation addresses ledipasvir’s formulation and dissolution characteristics. The claim does not cover every ledipasvir formulation. A formulation using a different polymer, a materially different active-to-polymer ratio, or predominantly crystalline ledipasvir would present a non-infringement position, subject to claim construction and equivalents analysis.

What crystalline form of sofosbuvir is required?

The claims require that more than 70% of the sofosbuvir is crystalline and that the crystalline material exhibits XRPD reflections at approximately:

6.1 degrees 2θ
12.7 degrees 2θ
20.1 degrees 2θ
20.8 degrees 2θ

Each reflection is defined with a tolerance of approximately plus or minus 0.2 degrees 2θ.

This is a solid-state limitation. A generic developer could attempt to avoid literal infringement by using a different polymorph, a different crystalline form, an amorphous form, or a product whose XRPD profile does not show the required reflections. That design-around would still need to satisfy pharmaceutical performance, stability and regulatory requirements.

How broad are the independent claims?

The patent has two principal types of independent protection.

Claim 1: broad formulation genus

Claim 1 covers a tablet comprising:

10% to 25% w/w of the ledipasvir/copovidone solid dispersion;
35% to 45% w/w sofosbuvir;
5% to 25% w/w lactose monohydrate;
5% to 25% w/w microcrystalline cellulose;
1% to 10% w/w croscarmellose sodium;
0.5% to 3% w/w colloidal silicon dioxide; and
0.1% to 3% w/w magnesium stearate.

The use of "comprising" makes the claim open-ended. Additional ingredients may be present, including a coating, colorants, processing aids or other excipients, provided the accused product still contains each recited component within the claimed ranges.

Claim 1 does not require the exact 1,000 mg tablet. It covers a range of compositions. The claim also does not require the exact 90 mg/400 mg strength, although the percentage ranges and solid-state requirements materially constrain the practical formulation space.

Claim 15: commercial percentage formulation

Claim 15 narrows the formulation to:

About 18% w/w ledipasvir/copovidone dispersion;
About 40% w/w sofosbuvir;
About 16.5% w/w lactose monohydrate;
About 18.0% w/w microcrystalline cellulose;
About 5.0% w/w croscarmellose sodium;
About 1.0% w/w colloidal silicon dioxide; and
About 1.5% w/w magnesium stearate.

These percentages total approximately 100%. Claim 15 is closely aligned with the commercial tablet core and is likely to be important in product-by-process review, ANDA litigation and technical infringement analysis.

Claim 16: commercial absolute-weight formulation

Claim 16 recites the same formulation in milligrams. The listed ingredients total 1,000 mg:

180 + 400 + 165 + 180 + 50 + 10 + 15 = 1,000 mg.

The claim requires the 180 mg solid dispersion, not merely 90 mg of ledipasvir. This distinction matters. A product containing 90 mg of ledipasvir in a different physical arrangement may not satisfy claim 16.

Which claims cover the Harvoni dosage strength?

Claims 3, 4, 15 and 16 most directly cover the commercial product.

Claim	Commercial relevance
Claim 3	Requires approximately 90 mg ledipasvir and 400 mg sofosbuvir
Claim 4	Adds the specified excipient quantities
Claim 15	Recites the commercial composition by weight percentage
Claim 16	Recites the commercial composition by absolute weight

Claim 5 adds a film coating. It is narrower than claims 1, 3, 4, 15 and 16 because the coating must be present.

A coated tablet can infringe claim 5, but the absence of a film coating does not avoid infringement of the underlying composition claims if all other limitations are met.

What method-of-use protection does US 10,039,779 provide?

Claims 6 through 14 cover treatment of an HCV-infected patient with the claimed tablet.

The treatment claims include:

Administration for 24 weeks or less;
Administration for 12 weeks or less;
Administration for 8 weeks or less;
Administration for 6 weeks or less;
Once-daily treatment;
HCV genotypes 1 through 6; and
Genotype 1a or 1b.

Claims 11, 13 and 14 are particularly important because they combine once-daily dosing with specified treatment durations and broad genotype coverage.

The method claims do not independently cover treatment with any ledipasvir/sofosbuvir product. They require administration of the fixed-dose tablet of claim 1. A generic product that avoids the formulation limitations may also reduce exposure to these method claims, although inducement and labeling theories remain relevant in litigation.

What solid-state and analytical evidence is needed to assess infringement?

A product-level infringement analysis would normally examine:

The quantitative composition of the tablet.
The identity and amount of copovidone.
The ledipasvir-to-copovidone ratio in the dispersion.
The amorphous fraction of ledipasvir.
The crystalline fraction of sofosbuvir.
XRPD data for the sofosbuvir component.
The amounts of lactose, microcrystalline cellulose, croscarmellose sodium, silicon dioxide and magnesium stearate.
The presence or absence of a film coating.
The proposed label and dosing regimen.

The XRPD requirement is a significant technical limitation. Testing must account for sample preparation, instrument calibration, peak broadening, preferred orientation and the interpretation of "about." A generic applicant could challenge whether the claimed reflections are inherent to the accused crystalline material or whether the product contains a different polymorph.

The amorphous-content limitation also creates evidentiary issues. "Greater than 70%" requires a quantitative or sufficiently reliable solid-state measurement. Differential scanning calorimetry, XRPD, solid-state NMR and related techniques may be relevant, depending on the patent’s specification and the parties’ expert positions.

When does US Patent 10,039,779 lose exclusivity?

The patent issued on August 7, 2018. Public patent-family records associate the patent with a 2013 priority framework. On a conventional 20-year patent-term calculation, the baseline expiration is approximately March 2034, before any patent-term adjustment, terminal disclaimer or other statutory modification is applied (USPTO, Patent Term Calculator; U.S. Patent No. 10,039,779).

Event	Date
Earliest reported priority framework	March 2013
U.S. patent issue	August 7, 2018
Conventional 20-year baseline	Approximately March 2034
Regulatory exclusivity for original Harvoni approval	Expired
Commercial generic risk	Driven by Orange Book challenges and settlements before patent expiration

Patent expiration does not guarantee commercial exclusivity until the expiration date. An ANDA applicant may file a Paragraph IV certification and litigate before expiration. A settlement may also establish an agreed generic launch date earlier than the patent-term endpoint.

What is the Orange Book status of US 10,039,779?

US Patent 10,039,779 is associated with the Harvoni product and is relevant to the Orange Book patent landscape for NDA 205834. The listing should be evaluated together with other Gilead patents covering ledipasvir, sofosbuvir, the combination product and related formulations, rather than as a standalone exclusivity right (FDA, Approved Drug Products with Therapeutic Equivalence Evaluations).

The Orange Book listing matters because:

An ANDA applicant must address listed patents.
A Paragraph IV certification can trigger patent litigation.
A 30-month stay may apply if the NDA holder or patent owner timely files suit.
The listed patent does not establish infringement automatically.
The scope of the listing can be narrower than the commercial product’s full patent estate.

The key diligence issue is whether the applicant certifies Paragraph IV against the formulation patent, Paragraph III until expiration, or another certification based on the patent’s listing and the proposed product.

Which companies have challenged Harvoni and related Gilead patents?

Publicly reported challenges to Gilead’s HCV patent estate have involved major generic and specialty pharmaceutical companies, including Teva, Mylan, Apotex, Cipla, Hetero, Torrent and Zydus-related entities. The relevant disputes have included patents covering sofosbuvir, ledipasvir, combination products and formulation technology.

The existence of a generic challenge does not establish that the challenger will launch the exact product covered by US 10,039,779. Litigation must be mapped patent by patent and claim by claim. A settlement involving a compound patent may not resolve a separate formulation patent unless the agreement expressly covers it.

What settlements and licensing deals affect generic entry?

Gilead entered licensing arrangements with the Medicines Patent Pool and selected generic manufacturers for certain HCV products in defined low- and middle-income markets. These agreements generally do not create unrestricted U.S. launch rights (Medicines Patent Pool, n.d.; Gilead Sciences, 2017).

U.S. generic entry has been influenced by patent settlements involving Gilead’s HCV portfolio. The principal commercial issue is whether a settlement permits an authorized or licensed generic before the relevant patent expiration date. The settlement date, licensed territory, product scope and covered patent family determine the practical effect.

For this patent, the relevant distinction is between:

A license to manufacture outside the United States;
A license for specified countries;
A U.S. authorized-generic arrangement;
A settlement allowing an ANDA launch on a fixed date; and
A settlement that excludes the specific formulation claims.

How strong is the patent estate for Harvoni?

The Harvoni estate is stronger in combination than US 10,039,779 alone.

Protection layer	Scope	Strategic value
Ledipasvir composition patents	Active ingredient and related compounds	Broad but subject to validity and term issues
Sofosbuvir patents	Active ingredient, salts and crystalline forms	Important for product blocking
Combination patents	Ledipasvir plus sofosbuvir	Covers the dual-active product
US 10,039,779	Specific tablet formulation and solid states	Strong product-specific coverage
Method-of-use patents	HCV treatment regimens	Supports label-based enforcement
Manufacturing patents	API and intermediate processes	Raises supply-chain and sourcing barriers

The formulation patent is technically specific but commercially relevant because the commercial product uses the claimed strengths and excipient architecture. Its vulnerability is that a challenger can target individual limitations through formulation design, polymorph selection or solid-dispersion changes.

What generic launch scenarios exist?

Three scenarios are commercially plausible.

Launch after negotiated settlement

The generic company launches on a contractually specified date. This may precede the baseline patent expiration and may involve a licensed formulation or an independently designed formulation.

At-risk launch after Paragraph IV litigation

The generic launches before final resolution of the patent dispute. Gilead may seek damages, an injunction or other relief. This scenario carries the highest exposure for the generic applicant.

Post-expiration launch with a redesigned formulation

The generic waits for patent expiration or settlement clearance and launches a product that avoids the claimed solid-state or formulation limitations. It may still face other Orange Book patents, regulatory exclusivity issues, supply constraints or separate litigation.

What is the revenue exposure?

Harvoni generated peak annual sales of roughly $13.9 billion in 2015 before declining as HCV treatment demand was absorbed and competing direct-acting antivirals expanded. Reported sales fell to approximately $9.1 billion in 2016, $4.4 billion in 2017 and $2.1 billion in 2018 (Gilead Sciences, 2016, 2018, 2019).

The remaining value of US 10,039,779 is therefore more relevant to:

Litigation leverage;
Portfolio-wide settlement economics;
Residual U.S. Harvoni sales;
Authorized-generic strategy; and
Precedent for Gilead’s formulation patent enforcement.

It is less likely to support the peak-value economics that existed shortly after Harvoni approval.

Key Takeaways

US 10,039,779 is a formulation patent for the ledipasvir/sofosbuvir fixed-dose tablet associated with Harvoni.
The core technical limitations are a 1:1 ledipasvir/copovidone solid dispersion, more than 70% amorphous ledipasvir and more than 70% crystalline sofosbuvir with specified XRPD peaks.
Claims 15 and 16 closely track the commercial 90 mg/400 mg, 1,000 mg tablet.
Claims 6 through 14 add HCV treatment, dosing-frequency, duration and genotype limitations.
The patent’s conventional term baseline is approximately March 2034, subject to the operative patent-term calculation.
Generic risk depends on Paragraph IV certifications, the full Orange Book estate, formulation design and any settlement license.
A competing product that changes the polymer, solid-state form or excipient architecture may have a credible design-around position.
The broader Harvoni patent estate is more commercially significant than this formulation patent considered in isolation.

FAQs

Does US 10,039,779 cover any ledipasvir and sofosbuvir tablet?

No. The tablet must satisfy the specified solid-dispersion, crystalline-sofosbuvir, excipient and percentage limitations.

Can a generic avoid the patent by changing only the film coating?

Usually not if the product still meets the underlying composition limitations. The film-coating limitation is separately recited in claim 5 and is not required by the principal uncoated composition claims.

Does 90 mg of ledipasvir alone satisfy claim 16?

No. Claim 16 requires approximately 180 mg of ledipasvir/copovidone solid dispersion containing approximately 90 mg of ledipasvir, plus the specified excipients and 400 mg of sofosbuvir.

Why are the sofosbuvir XRPD peaks important?

They identify the crystalline sofosbuvir form required by the claims. A product with a different solid-state form may present a literal non-infringement position.

Does a Harvoni patent settlement automatically clear US 10,039,779?

No. The settlement must expressly cover this patent or the relevant formulation claims. A settlement addressing a different Gilead patent may leave US 10,039,779 unresolved.

References

Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
Food and Drug Administration. (n.d.). Harvoni prescribing information. U.S. Department of Health and Human Services.
Gilead Sciences, Inc. (2016). 2015 annual report.
Gilead Sciences, Inc. (2018). 2017 annual report.
Gilead Sciences, Inc. (2019). 2018 annual report.
Medicines Patent Pool. (n.d.). Hepatitis C licensing and access programs.
United States Patent No. 10,039,779. (2018). Pharmaceutical compositions comprising ledipasvir and sofosbuvir. United States Patent and Trademark Office.
United States Patent and Trademark Office. (n.d.). Patent term calculator. U.S. Department of Commerce.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-002	Aug 28, 2019		RX	Yes	No	⤷ Start Trial	⤷ Start Trial			Y		⤷ Start Trial
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-001	Oct 10, 2014		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	095131	⤷ Start Trial
Argentina	130558	⤷ Start Trial
Australia	2014202687	⤷ Start Trial
Australia	2015202842	⤷ Start Trial
Australia	2016216641	⤷ Start Trial
Australia	2018203696	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,039,779

Which drugs does patent 10,039,779 protect, and when does it expire?

Summary for Patent: 10,039,779